OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55 nM, respectively.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:4.22 mg/mL (10 mM)

α2A adrenoceptor:2040 nM (ki), α2C adrenoceptor(ki):55 nM (ki), α2B adrenoceptor:285 nM (ki)

OPC-28326 augments microvessel growth and improves endothelial tube formation. OPC-28326 dose-dependently induces phosphorylation of eNOS and Akt without affecting total amounts of eNOS and Akt in HAECs[1].

OPC-28326 improves blood flow recovery in murine hindlimb ischemia and increases the number of capillaries in the ischemic leg[1]. In rats, intravenous administration of OPC-28326 (3 – 30 mg/kg) and yohimbine (0.3 – 3 mg/kg) results in a dose-dependent rightward shift in the pressor dose-response curve induced by B-HT 920 without affecting the mydriasis[2].